文献速递肝病

显著纤维化预测NASH患者新发糖尿病和动脉高血压

Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
PubMed 文献 · J Hepatol · 2020-03-06

该研究纳入178例代谢健康且经活检证实NAFLD的患者,随访5.6±4.4年,发现显著纤维化独立预测T2DM(HR 2.95)和AHT(HR 2.39),且HFS>0.12预测T2DM发生。

要点

  • 代谢健康的NAFLD患者中,显著纤维化增加新发T2DM和AHT风险。
  • HFS>0.12可预测T2DM发生,而NFS或FIB-4无此预测作用。
  • 显著纤维化患者中,肥胖进一步增加代谢结局风险。

核心结论

  • 代谢健康的NAFLD相关显著纤维化患者发生T2DM和AHT的风险更高。
  • HFS>0.12预测T2DM发生,而NFS或FIB-4无预测作用。

研究设计与样本

  • 来自HEPAmet注册研究(N=1,030)的178例代谢健康且经活检证实NAFLD的患者。
  • 计算HFS、NFS和FIB-4,随访从活检至诊断T2DM、AHT或血脂异常。

主要发现

  • 随访5.6±4.4年,T2DM发生9%(16/178),AHT发生8.4%(15/178)。
  • 多因素分析中,显著纤维化预测T2DM(HR 2.95;95%CI 1.19-7.31;p=0.019)和AHT(HR 2.39;95%CI 1.14-5.10;p=0.028)。
  • 显著纤维化患者T2DM年发病率4.4 vs. 1.2例/100人年,AHT为4.6 vs. 1.1例/100人年。
  • HFS>0.12预测T2DM风险(25% [4/16] vs. HFS<0.12 4.5% [4/88];logRank 6.658,p=0.010)。

关键数值与推荐

  • 显著纤维化定义基于活检。
  • HFS>0.12预测T2DM发生。

临床怎么用

  • 对代谢健康的NAFLD患者,应评估纤维化程度以识别T2DM和AHT高风险人群。
  • HFS>0.12可用于预测T2DM风险,辅助临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) could play a catalytic role in the development of metabolic comorbidities, although the magnitude of this effect in metabolically healthy patients with NAFLD remains unclear. We assessed the role of biopsy-proven NAFLD on the risk of developing type 2 diabetes mellitus (T2DM) and other metabolic comorbidities (arterial hypertension [AHT], and dyslipidemia) in metabolically healthy patients. METHODS: We included 178 metabolically healthy-defined by the absence of baseline T2DM, AHT, dyslipidemia-patients with biopsy-proven NAFLD from the HEPAmet Registry (N = 1,030). Hepamet fibrosis score (HFS), NAFLD fibrosis score, and Fibrosis-4 were calculated. Follow-up was computed from biopsy to the diagnosis of T2DM, AHT, or dyslipidemia. RESULTS: During a follow-up of 5.6 ± 4.4 years, T2DM occurred in 9% (16/178), AHT in 8.4% (15/178), low HDL in 9.6% (17/178), and hypertriglyceridemia in 23.6% (42/178) of patients. In multivariate analysis, significant fibrosis predicted T2DM and AHT. Independent variables related to T2DM appearance were significant fibrosis (HR 2.95; 95% CI 1.19-7.31; p = 0.019), glucose levels (p = 0.008), age (p = 0.007) and BMI (p = 0.039). AHT was independently linked to significant fibrosis (HR 2.39; 95% CI 1.14-5.10; p = 0.028), age (p = 0.0001), BMI (p = 0.006), glucose (p = 0.021) and platelets (p = 0.050). The annual incidence rate of T2DM was higher in patients with significant fibrosis (4.4 vs. 1.2 cases per 100 person-years), and increased in the presence of obesity, similar to AHT (4.6 vs. 1.1 cases per 100 person-years). HFS >0.12 predicted the risk of T2DM (25% [4/16] vs. HFS <0.12 4.5% [4/88]; logRank 6.658, p = 0.010). CONCLUSION: Metabolically healthy patients with NAFLD-related significant fibrosis were at greater risk of developing T2DM and AHT. HFS >0.12, but not NAFLD fibrosis score or Fibrosis-4, predicted the occurrence of T2DM. LAY SUMMARY: Patients with biopsy-proven non-alcoholic fatty liver disease and significant fibrosis were at risk of developing type 2 diabetes mellitus and arterial hypertension. The risk of metabolic outcomes in patients with significant fibrosis was increased in the presence of obesity. In addition to liver biopsy, patients at intermediate-to-high risk of significant fibrosis by Hepamet fibrosis score were at risk of type 2 diabetes mellitus.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ampuero J, Aller R, Gallego-Durán R, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J Hepatol. 2020. PMID: 32147361. doi:10.1016/j.jhep.2020.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。